AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Similar documents
AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Step Therapy Requirements. Effective: 1/1/2019

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Step Therapy Requirements. Effective: 05/01/2018

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

Step Therapy Requirements. Effective: 11/01/2018

ANTIDIABETIC AGENTS - MISCELLANEOUS

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details

ANTIDIABETIC AGENTS - MISCELLANEOUS

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

ANTIDIABETIC AGENTS - MISCELLANEOUS

FirstCarolinaCare Insurance Company. Step Therapy Requirements

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

ANTICONVULSANTS. Details

Step Therapy Requirements

ANTICONVULSANTS. Details

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

Step Therapy Requirements. Effective: 12/01/2016

Step Therapy Requirements. Effective: 03/01/2015

FirstCarolinaCare Insurance Company Step Therapy Requirements

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

ALLERGIC CONJUNCTIVITIS AGENTS

2017 Step Therapy Criteria

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

2018 Step Therapy Criteria

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.

ALPHA GLUCOSIDASE INHIBITOR THERAPY

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015)

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

ACYCLOVIR OINT (CCHP2017)

Step Therapy Medications

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

Step Therapy Criteria 2019

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

2018 Step Therapy FID 18088

ANTICONVULSANT STEP THERAPY

Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO) and Stride SM Value Rx Plus (HMO) Step Therapy Requirements

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

ACYCLOVIR OINT (CCHP2017)

Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO), Stride SM Value Rx Plus (HMO) and Stride SM Gain Rx (HMO)

2018 PDP Premier Step Therapy Document September 2018 Y0114_18_33144_I_009

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

SelectHealth Advantage 2018 Step Therapy Criteria. Previous trial on at least ONE: Generic topical acne treatment. Previous trial on: alendronate

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

ACYCLOVIR OINT (CCHP2017)

2017 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements

ADHD STIMULANTS-S(SHC)

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Optima Tier Gold Formulary Date Effective: November 1, 2018.

ACYCLOVIR OINT (CCHP2017)

Step Therapy Criteria

SelectHealth Advantage 2018 Step Therapy Criteria Previous trial on at least ONE: Generic topical acne treatment

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

**CRITERIA UNDER CMS REVIEW**

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

2019 Simply Step Therapy Document

2019 PDP Basic Step Therapy Document

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Health Choice Generations 1 Tier Gold Effective Date: 11/01/2018.

PPHP 2017 Formulary 2017 Step Therapy Criteria

CARE N CARE HEALTH PLAN

ANTICONVULSANT THERAPY

ALBUTEROL - SCORE{XE "ALBUTEROL - SCORE"}

ADHD STIMULANTS - SCORE

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

ATYPICAL ANTIPSYCHOTICS

SelectHealth Advantage 2019 Step Therapy Criteria Previous trial on at least ONE: Generic topical acne treatment

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

ADHD STIMULANTS - SCORE

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Farm Bureau Health Plans Date Effective: November 1, 2018.

Step Therapy Group Algorithm Steps

CARE N CARE HEALTH PLAN

CARE N CARE HEALTH PLAN

Step Therapy Criteria

Y0133_StepTherapyCriteria _C 10/18/18 Y0133_StepTherapyCriteria _C es 10/18/18

Transcription:

AMANTADINE ER OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE OSMOLEX ER 258 MG TABLET, PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. 1

ANTIDEPRESSANTS TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK VIIBRYD 10 MG TABLET VIIBRYD 20 MG TABLET VIIBRYD 40 MG TABLET PRIOR CLAIM FOR FORMULARY VERSION OF PAROXETINE, FLUOXETINE, SERTRALINE, DULOXETINE, CITALOPRAM, MIRTAZAPINE, ESCITALOPRAM, OR BUPROPION WITHIN THE PAST 120 DAYS. 2

ANTIDIABETIC AGENTS - MISCELLANEOUS GLYXAMBI 10 MG-5 MG TABLET GLYXAMBI 25 MG-5 MG TABLET INVOKAMET 150 MG-1,000 MG TABLET INVOKAMET 150 MG-500 MG TABLET INVOKAMET 50 MG-1,000 MG TABLET INVOKAMET 50 MG-500 MG TABLET INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE INVOKANA 100 MG TABLET INVOKANA 300 MG TABLET JARDIANCE 10 MG TABLET JARDIANCE 25 MG TABLET SYNJARDY 12.5 MG-1,000 MG TABLET SYNJARDY 12.5 MG-500 MG TABLET SYNJARDY 5 MG-1,000 MG TABLET SYNJARDY 5 MG-500 MG TABLET SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE PRIOR CLAIM FOR METFORMIN, METFORMIN ER, A SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), PIOGLITAZONE, OR COMBINATION OF A SULFONYLUREA-METFORMIN WITHIN THE PAST 120 DAYS. 3

ANTI-INFLAMMATORY AGENTS - GI DIPENTUM 250 MG CAPSULE PRIOR CLAIM FOR ANY 1 OF THE FOLLOWING: BALSALAZIDE, APRISO, DELZICOL, MESALAMINE DR 800 MG TAB, OR FORMULARY MESALAMINE 1.2 G DR TAB WITHIN THE PAST 120 DAYS. 4

ANTIPSYCHOTIC AGENTS aripiprazole 10 mg disintegrating tablet aripiprazole 15 mg disintegrating tablet clozapine 100 mg disintegrating tablet clozapine 12.5 mg disintegrating tablet clozapine 150 mg disintegrating tablet clozapine 200 mg disintegrating tablet clozapine 25 mg disintegrating tablet FANAPT 1 MG TABLET FANAPT 10 MG TABLET FANAPT 12 MG TABLET FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK FANAPT 2 MG TABLET FANAPT 4 MG TABLET FANAPT 6 MG TABLET FANAPT 8 MG TABLET SAPHRIS (BLACK CHERRY) 10 MG SUBLINGUAL TABLET SAPHRIS (BLACK CHERRY) 5 MG SUBLINGUAL TABLET SAPHRIS 10 MG SUBLINGUAL TABLET SAPHRIS 2.5 MG SUBLINGUAL TABLET SAPHRIS 5 MG SUBLINGUAL TABLET VERSACLOZ 50 MG/ML ORAL SUSPENSION VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK VRAYLAR 1.5 MG CAPSULE VRAYLAR 3 MG CAPSULE VRAYLAR 4.5 MG CAPSULE VRAYLAR 6 MG CAPSULE PRIOR CLAIM FOR FORMULARY VERSIONS OF ANY TWO ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE WITHIN THE PAST 365 DAYS. 5

ANTIPSYCHOTIC AGENTS II REXULTI 0.25 MG TABLET REXULTI 0.5 MG TABLET REXULTI 1 MG TABLET REXULTI 2 MG TABLET REXULTI 3 MG TABLET REXULTI 4 MG TABLET PRIOR CLAIM FOR TWO (2) OF THE FOLLOWING FORMULARY ORAL VERSIONS OF ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE OR ZIPRASIDONE) OR SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE) OR SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS 6

ANTIULCER AGENTS DEXILANT 30 MG CAPSULE, DELAYED RELEASE DEXILANT 60 MG CAPSULE, DELAYED RELEASE rabeprazole 20 mg tablet,delayed release PRIOR CLAIM FOR GENERIC FEDERAL LEGEND ORAL OMEPRAZOLE, PANTOPRAZOLE, OR LANSOPRAZOLE WITHIN THE PAST 120 DAYS. 7

B VERSUS D ADMINISTRATIVE STEP CYCLOPHOSPHAMIDE 25 MG CAPSULE CYCLOPHOSPHAMIDE 50 MG CAPSULE methotrexate sodium 2.5 mg tablet XATMEP 2.5 MG/ML ORAL SOLUTION IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG. 8

ELUXADOLINE VIBERZI 100 MG TABLET VIBERZI 75 MG TABLET PRIOR CLAIM FOR DICYCLOMINE AND XIFAXAN 550MG WITHIN THE PAST 365 DAYS. 9

FIDAXOMICIN DIFICID 200 MG TABLET PRIOR CLAIM FOR ORAL VANCOMYCIN IN THE PAST 120 DAYS. 10

GABAPENTIN SR GRALISE 300 MG TABLET,EXTENDED RELEASE GRALISE 30-DAY STARTER PACK 300 MG (9)-600 MG (69) TABLET,EXT. RELEASE GRALISE 600 MG TABLET,EXTENDED RELEASE PRIOR CLAIM FOR GABAPENTIN IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. 11

INSULIN/GLP-1 ANALOG SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN PRIOR CLAIM FOR 2 OF THE FOLLOWING (ONE FROM EACH GROUP): A) VICTOZA, LANTUS, TOUJEO, OR OZEMPIC AND B) METFORMIN, METFORMIN ER, SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), COMBO SULFONYLUREA- METFORMIN, OR PIOGLITAZONE IN PAST 365 DAYS. 12

NOVEL ORAL ANTICOAGULANTS PRADAXA 110 MG CAPSULE PRADAXA 150 MG CAPSULE PRADAXA 75 MG CAPSULE PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS. 13

OPHTHALMIC ANTIHISTAMINES ALREX 0.2 % EYE DROPS,SUSPENSION BEPREVE 1.5 % EYE DROPS PRIOR CLAIM FOR ONE OF THE FOLLOWING: OTC LORATADINE, OTC LORATADINE D, OTC CETIRIZINE, OTC CETIRIZINE D, OTC FEXOFENADINE, OTC FEXOFENADINE D, OTC LEVOCETIRIZINE, OTC GENERIC KETOTIFEN EYE DROPS 0.025%, LEVOCETIRIZINE, CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS. 14

RENIN ANGIOTENSIN SYSTEM INHIBITORS TEKTURNA 150 MG TABLET TEKTURNA 300 MG TABLET TEKTURNA HCT 150 MG-12.5 MG TABLET TEKTURNA HCT 150 MG-25 MG TABLET TEKTURNA HCT 300 MG-12.5 MG TABLET TEKTURNA HCT 300 MG-25 MG TABLET PRIOR CLAIM FOR AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE INHIBITOR), OR ACE INHIBITOR COMBINATION OR A GENERIC ANGIOTENSIN RECEPTOR BLOCKER (ARB), OR GENERIC ARB COMBINATION WITHIN THE PAST 120 DAYS. 15

SPRITAM SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION SPRITAM 250 MG TABLET FOR ORAL SUSPENSION SPRITAM 500 MG TABLET FOR ORAL SUSPENSION SPRITAM 750 MG TABLET FOR ORAL SUSPENSION PRIOR CLAIM FOR LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS 16

INDEX ALREX 0.2 % EYE DROPS,SUSPENSION... 14 aripiprazole 10 mg disintegrating tablet... 5 aripiprazole 15 mg disintegrating tablet... 5 BEPREVE 1.5 % EYE DROPS...14 clozapine 100 mg disintegrating tablet...5 clozapine 12.5 mg disintegrating tablet...5 clozapine 150 mg disintegrating tablet...5 clozapine 200 mg disintegrating tablet...5 clozapine 25 mg disintegrating tablet... 5 CYCLOPHOSPHAMIDE 25 MG CAPSULE...8 CYCLOPHOSPHAMIDE 50 MG CAPSULE...8 DEXILANT 30 MG CAPSULE, DELAYED RELEASE...7 DEXILANT 60 MG CAPSULE, DELAYED RELEASE...7 DIFICID 200 MG TABLET... 10 DIPENTUM 250 MG CAPSULE... 4 FANAPT 1 MG TABLET... 5 FANAPT 10 MG TABLET... 5 FANAPT 12 MG TABLET... 5 FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK... 5 FANAPT 2 MG TABLET... 5 FANAPT 4 MG TABLET... 5 FANAPT 6 MG TABLET... 5 FANAPT 8 MG TABLET... 5 GLYXAMBI 10 MG-5 MG TABLET...3 GLYXAMBI 25 MG-5 MG TABLET...3 GRALISE 300 MG TABLET,EXTENDED RELEASE... 11 GRALISE 30-DAY STARTER PACK 300 MG (9)-600 MG (69) TABLET,EXT. RELEASE... 11 GRALISE 600 MG TABLET,EXTENDED RELEASE... 11 INVOKAMET 150 MG-1,000 MG TABLET... 3 INVOKAMET 150 MG-500 MG TABLET... 3 INVOKAMET 50 MG-1,000 MG TABLET... 3 INVOKAMET 50 MG-500 MG TABLET... 3 INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE... 3 INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE... 3 INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE... 3 INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE... 3 INVOKANA 100 MG TABLET...3 INVOKANA 300 MG TABLET...3 JARDIANCE 10 MG TABLET... 3 JARDIANCE 25 MG TABLET... 3 methotrexate sodium 2.5 mg tablet... 8 OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE... 1 OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE... 1 OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE... 1 PRADAXA 110 MG CAPSULE... 13 PRADAXA 150 MG CAPSULE... 13 PRADAXA 75 MG CAPSULE... 13 rabeprazole 20 mg tablet,delayed release...7 REXULTI 0.25 MG TABLET...6 REXULTI 0.5 MG TABLET...6 REXULTI 1 MG TABLET... 6 REXULTI 2 MG TABLET... 6 REXULTI 3 MG TABLET... 6 REXULTI 4 MG TABLET... 6 SAPHRIS (BLACK CHERRY) 10 MG SUBLINGUAL TABLET...5 SAPHRIS (BLACK CHERRY) 5 MG SUBLINGUAL TABLET...5 SAPHRIS 10 MG SUBLINGUAL TABLET... 5 SAPHRIS 2.5 MG SUBLINGUAL TABLET... 5 SAPHRIS 5 MG SUBLINGUAL TABLET... 5 SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN...12 17

SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION...16 SPRITAM 250 MG TABLET FOR ORAL SUSPENSION...16 SPRITAM 500 MG TABLET FOR ORAL SUSPENSION...16 SPRITAM 750 MG TABLET FOR ORAL SUSPENSION...16 SYNJARDY 12.5 MG-1,000 MG TABLET... 3 SYNJARDY 12.5 MG-500 MG TABLET... 3 SYNJARDY 5 MG-1,000 MG TABLET... 3 SYNJARDY 5 MG-500 MG TABLET...3 SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE... 3 SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE... 3 SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE... 3 SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE... 3 TEKTURNA 150 MG TABLET... 15 TEKTURNA 300 MG TABLET... 15 TEKTURNA HCT 150 MG-12.5 MG TABLET... 15 TEKTURNA HCT 150 MG-25 MG TABLET... 15 TEKTURNA HCT 300 MG-12.5 MG TABLET... 15 TEKTURNA HCT 300 MG-25 MG TABLET... 15 TRINTELLIX 10 MG TABLET... 2 TRINTELLIX 20 MG TABLET... 2 TRINTELLIX 5 MG TABLET... 2 VERSACLOZ 50 MG/ML ORAL SUSPENSION... 5 VIBERZI 100 MG TABLET...9 VIBERZI 75 MG TABLET... 9 VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK... 2 VIIBRYD 10 MG TABLET... 2 VIIBRYD 20 MG TABLET... 2 VIIBRYD 40 MG TABLET... 2 VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK...5 VRAYLAR 1.5 MG CAPSULE... 5 VRAYLAR 3 MG CAPSULE... 5 VRAYLAR 4.5 MG CAPSULE... 5 VRAYLAR 6 MG CAPSULE... 5 XATMEP 2.5 MG/ML ORAL SOLUTION... 8 XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN...12 18